Stevens RJ , Andujar C , Edwards CJ et al. Thalidomide in treatment of the cutaneous manifestations of Lupus Erythematosus: experience in sixteen consecutive patients . Br J Rheumatol1997; 36: 353–359 .
3.
Atra E , Sato EI . Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide . Clin Exp Rheumatol1993; 11: 487–493 .
4.
Darvay A , Basarab T , Russell-Jones R . Thalidomide-induced toxic pustuloderma . Clin Exp Dermatol1997; 22: 297–299 .
5.
Staugton RCD , Rowland-Payne CME , Harper JL , McMichen H . Toxic pustuloderma: a new entity . JR Soc Med1984; 77 (Suppl 4): 6–8 .
6.
Roujeau JC , Bioulac-Sage P , Bourseau C et al. Acute generalised exanthematous pustulosis . Arch Dermatol1991; 127: 1333–1338 .
7.
Wintroub BU , Stern RS , Arndt KA . Cutaneous reaction to drug. In: Fitzpatrick TB , Eisen AZ , Wolff K et al, eds. Dermatology in General Medicine, New York: McGraw-Hill , 1987: 1387–1466.
8.
Yell JA et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis . Br J Dermatol1995; 132: 921–928 .
9.
Lance NJ , Blaszak W and Swartz TJ . Bullous Skin lesion in Systemic Lupus Erythematosus . Semin Arthritis Rheum1991; 20: 396–404 .
10.
Powell RJ , Gardner-Medwin JMM . Guideline for the clinical use and dispensing of Thalidomide . Postgrad Med J1994; 70: 901–904 .
